-
Posted by
Two Blokes Mon at 3:01 PM -
Filed in
Stock
-
2 views
BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product.
